CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Carotid Artery Reactivity TestingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug2435 Responsive training with no video feedback Wiki 1.00
drug2436 Responsive training with video feedback Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D001321 Autistic Disorder NIH 0.38
D000067877 Autism Spectrum Disorder NIH 0.33

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0000717 Autism HPO 0.38
HP:0000729 Autistic behavior HPO 0.33

There is one clinical trial.

Clinical Trials

1 Influence of COVID-19 on Vascular Endothelial Function

Rationale: Infection with severe acute respiratory syndrome coronavirus (SARS-CoV) 2 could result in endothelial dysfunction with increased risk of arterial thrombotic events by downregulating the expression of angiotensin converting enzyme 2 (ACE2). Endothelial function can be easily and non-invasively determined by carotid artery reactivity (CAR) testing. Objective: To investigate the predictive value of endothelial dysfunction, measured by carotid artery reactivity testing, for 1-year cardiovascular events in patients with past COVID-19 infection. Study design: A prospective observational longitudinal cohort study. Study population: Patients recovered from confirmed infection with SARS-CoV2. Main study parameters/endpoints: macrovascular endothelial function measured by carotid artery reactivity testing.

NCT04468412 COVID Vascular; Damage Diagnostic Test: Carotid Artery Reactivity Testing

Primary Outcomes

Description: Change in endothelial dysfunction as determined by CAR test.

Measure: Endothelial dysfunction

Time: CAR will be measures between 6 and 20 weeks and 1 year after recovery from COVID-19.

Secondary Outcomes

Description: MACE include non-fatal myocardial infarction, non-fatal ischemic stroke, acute limb ischemia, need for revascularization, amputation and cardiovascular death.

Measure: Major adverse cardiovascular events (MACE)

Time: 1 year

No related HPO nodes (Using clinical trials)